RT Journal Article
SR Electronic
T1 FutureMS Cohort Profile: A Scottish Multi-Centre Inception Cohort Study of Relapsing-Remitting Multiple Sclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.15.21253274
DO 10.1101/2021.04.15.21253274
A1 Kearns, P.K.A.
A1 Martin, S.J.
A1 Chang, J.
A1 Meijboom, R.
A1 York, E.N.
A1 Chen, Y.
A1 Weaver, C.
A1 Stenson, A.
A1 Hafezi, K.
A1 Freyer, E.
A1 Murphy, L.
A1 Harroud, A.
A1 Foley, P.
A1 Hunt, D.
A1 McLeod, M.
A1 O’Riordan, J.
A1 Carod-Artal, F.J.
A1 MacDougall, N.J.J.
A1 Baranzini, S.E.
A1 Waldman, A.D.
A1 Connick, P.
A1 Chandran, S.
YR 2021
UL http://medrxiv.org/content/early/2021/04/22/2021.04.15.21253274.abstract
AB Multiple Sclerosis (MS) is an immune-mediated, neuroinflammatory disease of the central nervous system and in industrialised countries the most common cause of progressive neurological disability in working age persons. However, there is significant between-subject heterogeneity in disease activity and response to treatment. Currently, the ability to predict at diagnosis who will have a benign, intermediate, or aggressive disease course is very limited. There is therefore a need for integrated predictive tools to inform individualised treatment decision making. FutureMS is a nationally-representative, prospective observation cohort study comprising 440 participants with a new diagnosis of relapsing remitting MS living in Scotland between May 2016 and March 2019. Established with the aim of addressing this need for individualised predictive tools, the cohort is designed to combine detailed clinical phenotyping with imaging, genetic and biomarker metrics of disease activity and progression. Recruitment, baseline assessment and follow up at year one is complete and longer-term follow up is planned, beginning at five years after first visit. The study aims to address the biology and determinants of disease heterogeneity in MS. Here we describe the cohort design and present a profile of the participants at baseline and one year of follow up.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is indebted to the FutureMS participants. We would like to thank non-author contributors of the FutureMS Consortium and clinical collaborators within neurology departments across NHS Scotland. With thanks to FutureMS, hosted by Precision Medicine Scotland Innovation Centre [PMS-IC] and funded by a grant from the Scottish Funding Council to Precision Medicine Scotland Innovation Centre (PMS IC) and Biogen Idec Ltd Insurance. PK is supported by ECAT/Wellcome fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study is conducted in conformity with the declaration of Helsinki, ICH guidelines for Good Clinical Practice (CPMP/ICH/135/95), and with ethical approval granted from the National Health Service (NHS) South East Scotland Research Ethics Committee (REC02) (Reference: 15/SS/0233) and sponsor research and development approval granted from individual NHS Board Research and Development departments and the University of Edinburgh (IRAS Project ID: 169955). Control samples were collected under ethical approval granted from the NHS East of Scotland Research Ethics committee (REC01) as part of the Scottish Regenerative Neurology Tissue Bank Project (Reference: 15/ES/0094).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData requests from a third party will be handled on a case by case basis by the steering committee and data custodians.